Catherine Martinelli

Discussing the value of the subsidiary OmniaBio, as soveriegn capacity that is critical to Canada's needs in the event of future pandemics or national emergency, leading to support from federal entitities that supply capital and other financial products. Continued effort to maintain strong support for strategic value of the Strategic Response Fund support for the project re the application of automation and AI technology in our recently opened cell and gene therapy manufacutring facility operated by the subsidiary OmniaBio. The support will result in lower cost of life saving cell and gene therapy products. Pursue opportunities to benefit the Canadian cell and gene therapy ecosystem caused by global uncertainty.

Meetings with elected and non elected officials regarding an investment to modernize the company's Boucherville site.